Audited Supplier
HNB-phosphoric acid
54-21-7
C7h5nao3
/
Nutritional
ISO, FDA
Metal
Frozen
2 Years Proper Storage
99%
Sodium Salicylate
54-21-7
160.103
C7h5nao3
/
HPLC99%
10g Available
Yes
Medical Additives
GMP/ISO9001
Carton Box or Drum
Tt/Western Union
HNB
Carton Box
HPLC 99%
China
3006920000
Product Description
Cas: 54-21-7 Sodium Salicylate powder
| product name | Sodium Salicylate |
| cas number | 54-21-7 |
| apperance | White crystal powder |
| Density | 2.2±0.1 g/cm3 |
| MF | C7H5NaO3 |
| MW | 160.103 |
Sodium salicylate is a potent inhibitor of COX-2 activity at concentrations well below those required to inhibit NF-κB (20 mg/mL) activation. When added with interleukin 1β for 24 h, sodium salicylate inhibits prostaglandin E2 release with an IC50 value of 5 μg/mL, and this effect is independent of NF-κB activation or COX-2 transcription or translation. Acute (30 min) sodium salicylate also causes concentration-dependent inhibition of COX-2 activity in the presence of 0, 1, or 10 μM exogenous arachidonic acid. In contrast, sodium salicylate is a very weak inhibitor of COX-2 activity with IC50 > 100 μg/mL when exogenous arachidonic acid is increased to 30 μM. When added with IL-1β for 24 h, sodium salicylate causes a concentration-dependent inhibition of PGE2 release with an apparent IC50 value of approximately 5 μg/mL. The ability of sodium salicylate to directly inhibit COX-2 activity in A549 cells is tested after 30 min of exposure, followed by the addition of different concentrations of exogenous arachidonic acid (1, 10, and 30 μM). In the absence of arachidonic acid addition or in the presence of 1 or 10 μM exogenous substrate, sodium salicylate causes a concentration-dependent inhibition of COX-2 activity with an apparent IC50 value of approximately 5 μg/mL. However, sodium salicylate is an ineffective inhibitor of COX-2 activity when the same experiment is performed with 30 μM arachidonic acid, with an apparent IC50 value greater than 100 μg/mL, and maximum inhibition is achieved of less than 50%[1].
